Eledon Pharmaceuticals Inc
ELDN
Get informed when a big investor buys or sells
+ FollowMarket Cap$202.23M
Close$
$0.27
89.8% downside
Current Fair Value
89.8% downsideOvervalued by 89.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $202.23 Million |
|---|---|
| Enterprise Value | $195.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.56 |
| Beta | 0.94 |
| Outstanding Shares | 113,631,565 |
Return
| Return on Equity | -298.55% |
|---|---|
| Return on Assets | -78.16% |
| Return on Invested Capital | -64.94% |
Valuation & Multiples
| P/E Ratio | -2.65 |
|---|---|
| PEG | -1.45 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.64 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 8.9722▲ 897.22% |
|---|---|
| Total Calls | 89,800▼ 4.37% |
| Total Puts | 805,700▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.47%▲ 3.56% |
|---|---|
| Total Invested | $185.61M▲ 41.44% |
| Investors Holding | 169▲ 46.00% |
ESG Score
No data
About Eledon Pharmaceuticals Inc
10 employees
CEO: Gregory Flesher Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-bas...